BioSpace News Archive

Rising geriatric population, coupled with the rapid increase in the incidence of various chronic diseases are favouring the upward trajectory of the global medical clothing market.

Solutions offered by the players and service providers in the global clinical workflow solutions market enable smooth flow of real time data pertaining to the healthcare sector.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per a recent market study by Fact.MR, the global patient positioning system market stood at US$ 1 Bn in 2020.

Virtual care refers to a technique that allows for the treatment of patients dealing with different health issues with the help of advanced technologies such as audio, video, or written communication.

Illumina, Inc. announced an agreement with Israel’s Ministry of Health for a pilot program to implement the use of whole-genome sequencing in critically-ill infants suspected of having a genetic disorder in neonatal intensive care units.

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2021 financial results before the market opens on Wednesday, November 3, 2021 .

RepliCel Life Sciences Inc., a company developing next-generation technologies in aesthetics and orthopedics, provided an update on its dermal injector program.

The Medicines Patent Pool and Merck, known as MSD outside the United States and Canada, announced the signing of a voluntary licensing agreement to facilitate affordable global access for molnupiravir, an investigational oral COVID-19 antiviral medicine for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization.

Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the third quarter ended October 2, 2021.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced enrollment of the first psoriasis patient in Part C of its ongoing phase 1 clinical trial of IMU-935, a highly potent and selective inverse agonist of the transcription factor RORγt.